Ristfor: Uses, Dosage & Side Effects
Sitagliptin/metformin fixed-dose combination for type 2 diabetes
Quick Facts About Ristfor
Key Takeaways About Ristfor
- Two mechanisms in one tablet: Sitagliptin boosts the incretin system to increase insulin release after meals, while metformin reduces hepatic glucose output and improves insulin sensitivity
- Twice-daily dosing: One 50 mg/850 mg tablet is taken in the morning and one in the evening, both with meals to reduce stomach side effects
- Stronger HbA1c reduction: The combination typically lowers HbA1c by approximately 1.5–2.0 percentage points, more than either component alone
- Low hypoglycemia risk alone: Neither sitagliptin nor metformin stimulates insulin release independently of glucose, so the risk of low blood sugar is low unless combined with a sulfonylurea or insulin
- Serious safety points: Lactic acidosis (rare but life-threatening) and pancreatitis are known risks; Ristfor must be stopped around iodinated contrast imaging and major surgery, and is contraindicated in severe renal impairment
What Is Ristfor and What Is It Used For?
Ristfor is a fixed-dose combination tablet of sitagliptin (a DPP-4 inhibitor) and metformin (a biguanide) used to treat type 2 diabetes in adults. It is prescribed when metformin alone is no longer enough to control blood sugar, or as a single-tablet replacement for patients already taking both drugs. Ristfor lowers HbA1c by targeting two different pathways in glucose regulation at the same time.
Ristfor is an oral antidiabetic medication that brings together two well-established glucose-lowering drugs, sitagliptin and metformin, in a single film-coated tablet. It is indicated for adults with type 2 diabetes mellitus as an addition to diet and exercise, with the goal of improving long-term glycemic control and reducing the risk of diabetes-related complications. Because the two ingredients work through different but complementary mechanisms, their combined effect is greater than either drug achieves alone.
According to the European Medicines Agency (EMA) Summary of Product Characteristics, Ristfor is approved in three clinical scenarios. First, in patients whose blood sugar remains above target despite the maximum tolerated dose of metformin monotherapy. Second, as a combination with a sulfonylurea (for example glimepiride or glipizide) when dual therapy of metformin plus sulfonylurea does not achieve adequate glycemic control. Third, in combination with insulin when stable insulin therapy together with metformin alone is insufficient. A fourth, very common real-world use is simply as a more convenient replacement for patients who are already taking separate sitagliptin and metformin tablets.
Ristfor is not a cure for type 2 diabetes and does not replace the cornerstones of diabetes care: a balanced diet, regular physical activity, weight management, and smoking cessation. Rather, it is a long-term tool that works best when these lifestyle measures are continued. International guidelines, including the American Diabetes Association (ADA) Standards of Care 2025 and NICE NG28, recognize DPP-4 inhibitors combined with metformin as a reasonable second-line option, particularly when minimizing hypoglycemia and weight gain is a priority.
What is type 2 diabetes?
Type 2 diabetes is a chronic metabolic disease characterized by persistently elevated blood sugar (hyperglycemia) caused by a combination of insulin resistance in muscle, liver, and fat tissue, and a progressive decline in insulin-producing beta-cell function in the pancreas. Over years, the body's own compensation mechanisms fail, and blood glucose rises above the normal range. Without effective treatment, type 2 diabetes increases the risk of microvascular complications (retinopathy, nephropathy, neuropathy) and macrovascular events (myocardial infarction, stroke, peripheral arterial disease).
Modern diabetes care aims not only to lower HbA1c to an individualized target (commonly below 7.0% or 53 mmol/mol for most adults), but also to reduce cardiovascular and renal risk. Treatment typically follows a stepwise approach: lifestyle modification, then metformin as first-line pharmacotherapy, followed by additional drugs such as DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, sulfonylureas, or insulin, depending on the patient's profile. Fixed-dose combinations like Ristfor simplify the regimen and improve adherence, which is itself a determinant of long-term outcomes.
How do sitagliptin and metformin work together?
Sitagliptin inhibits the enzyme dipeptidyl peptidase-4 (DPP-4). This enzyme normally breaks down two incretin hormones, GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), which are released from the gut after eating. By inhibiting DPP-4, sitagliptin prolongs the activity of these hormones, which in turn stimulates insulin release from pancreatic beta cells and suppresses glucagon release from alpha cells – but only when blood glucose is elevated. This glucose-dependent action gives sitagliptin its characteristic low risk of hypoglycemia.
Metformin is a biguanide that acts primarily by reducing hepatic glucose production (gluconeogenesis), in part through activation of the AMP-activated protein kinase (AMPK) pathway in the liver. It also decreases intestinal glucose absorption and improves insulin sensitivity in peripheral tissues. Metformin has been in clinical use since the late 1950s, is included on the WHO Model List of Essential Medicines, and is widely accepted as the preferred first-line oral therapy for type 2 diabetes because of its efficacy, low cost, favorable weight profile, and cardiovascular safety.
The two ingredients target different glucose-regulating pathways – sitagliptin enhances post-meal insulin secretion and blunts glucagon, while metformin suppresses liver glucose output and improves insulin sensitivity. Clinical trials have shown that the combination lowers HbA1c by approximately 1.5–2.0 percentage points from baseline, compared with about 0.5–0.8 points for sitagliptin alone or 1.0–1.5 points for metformin alone. Neither drug significantly increases insulin levels when glucose is normal, so hypoglycemia remains uncommon unless another insulin-stimulating drug is added.
What Should You Know Before Taking Ristfor?
Do not take Ristfor if you have severe kidney impairment, acute metabolic acidosis (including diabetic ketoacidosis), type 1 diabetes, a condition that can cause poor tissue oxygenation (such as heart failure or severe infection), severe liver disease, or hypersensitivity to either ingredient. Tell your doctor about kidney or liver disease, heart problems, alcohol use, upcoming surgery, or planned contrast imaging before starting treatment.
A careful pre-treatment assessment is essential before Ristfor is prescribed. The combination adds the safety profile of sitagliptin to that of metformin, so your doctor will check your kidney function (eGFR), liver function, cardiovascular status, and hydration. Your full medication list – including prescription drugs, over-the-counter products, and supplements – should be reviewed to identify interactions. Open communication with your healthcare provider throughout treatment is vital for safe and effective diabetes management.
Contraindications
You must not take Ristfor in any of the following situations, because the risks clearly outweigh the benefits:
- Known hypersensitivity to sitagliptin, metformin, or any of the excipients in the tablet. Serious hypersensitivity reactions to sitagliptin, including anaphylaxis, angioedema, and exfoliative skin conditions such as Stevens-Johnson syndrome, have been reported in post-marketing surveillance.
- Diabetic ketoacidosis (DKA) or diabetic pre-coma. These are acute metabolic emergencies that require immediate insulin therapy, not oral antidiabetic drugs.
- Severe renal impairment – typically an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2. Reduced clearance of metformin increases the risk of lactic acidosis.
- Acute conditions with the potential to alter renal function, such as dehydration, severe infection, or shock.
- Conditions that can cause tissue hypoxia, particularly decompensated heart failure, recent myocardial infarction, respiratory failure, and severe shock.
- Acute or chronic disease that may cause tissue hypoxia, such as respiratory failure or recent myocardial infarction.
- Hepatic impairment or acute alcohol intoxication, alcoholism. Both increase lactic acidosis risk with metformin.
- Pregnancy and breastfeeding, as discussed in the dedicated section below.
Type 1 diabetes is not an approved indication for Ristfor. Patients with type 1 diabetes require insulin therapy, and oral antidiabetic drugs cannot replace insulin in this setting. Using Ristfor in place of insulin in type 1 diabetes would rapidly lead to dangerous hyperglycemia and ketoacidosis.
Warnings and Precautions
Several situations require extra caution, closer monitoring, or temporary discontinuation of Ristfor. Tell your doctor before taking Ristfor if you have or have had any of the following:
- Kidney disease: Kidney function should be measured before starting treatment and monitored at least annually (more often in elderly patients or patients with borderline eGFR). Ristfor is not recommended if eGFR is below 45 mL/min and is contraindicated below 30 mL/min.
- Risk of lactic acidosis: This rare but life-threatening metabolic complication is associated with metformin. Risk factors include kidney dysfunction, severe dehydration (from diarrhea or vomiting), severe infection, shock, heart failure, liver disease, and excessive alcohol intake. Warning signs – muscle cramps, unusual tiredness, difficulty breathing, stomach pain, a low body temperature, or a slow or irregular heartbeat – require stopping Ristfor and seeking emergency care immediately.
- Iodinated contrast imaging: Intravascular iodinated contrast can impair renal function and raise lactic acidosis risk. Ristfor should be temporarily stopped before or at the time of the examination and resumed only after kidney function is reassessed and confirmed to be stable, typically after at least 48 hours.
- Surgery: Ristfor must be stopped at the time of, or prior to, surgery under general, spinal, or epidural anaesthesia. Treatment may be resumed after normal food and fluids are re-established and kidney function is confirmed stable.
- Pancreatitis: Cases of acute pancreatitis, including fatal and non-fatal haemorrhagic or necrotising pancreatitis, have been reported with sitagliptin-containing products. If pancreatitis is suspected, Ristfor must be stopped.
- Bullous pemphigoid: Rare cases of this blistering skin disease have been reported with DPP-4 inhibitors. Stop Ristfor if bullous pemphigoid is suspected.
- Vitamin B12 deficiency: Long-term metformin use is associated with reduced absorption of vitamin B12, which can contribute to anaemia or neurological symptoms. Periodic monitoring of vitamin B12 status is recommended.
- Severe joint pain: Post-marketing reports have linked DPP-4 inhibitors to cases of severe, sometimes disabling arthralgia. Contact your doctor if you develop severe or persistent joint pain.
- Hypoglycemia risk in combination: When Ristfor is added to a sulfonylurea or insulin, the dose of the sulfonylurea or insulin may need to be reduced to lower the risk of low blood sugar.
- Feeling very weak, tired, or unusual sleepy
- Severe nausea, vomiting, or stomach pain, often with diarrhea
- Rapid or deep breathing, or shortness of breath
- Muscle cramps or aching
- Feeling very cold, especially in the hands or feet, or a drop in body temperature
- A slow, fast, or irregular heartbeat
- Confusion, dizziness, or fainting
Pregnancy and Breastfeeding
Ristfor is not recommended during pregnancy. There is insufficient clinical safety data on the sitagliptin component in pregnant women, and reproductive animal studies have shown some toxicity at high doses. Metformin crosses the placenta, and although it has been used in some pregnancies (for example in polycystic ovary syndrome or gestational diabetes under specialist care), the fixed-dose combination Ristfor is not approved for use during pregnancy. If you become pregnant or plan to become pregnant, contact your doctor as soon as possible. Insulin is generally the preferred treatment for achieving tight glucose control in pregnancy.
Metformin is excreted in small amounts in human breast milk. Data on the excretion of sitagliptin into breast milk are limited, and animal studies indicate that sitagliptin is present in breast milk. Because of the lack of sufficient safety data for the combination, Ristfor should not be used during breastfeeding. Discuss alternative diabetes management with your healthcare provider if you are breastfeeding or planning to breastfeed.
Children and Adolescents
The safety and efficacy of Ristfor in children and adolescents under 18 years of age have not been established. Clinical trials of sitagliptin in pediatric type 2 diabetes did not demonstrate significant HbA1c improvements compared with placebo. Metformin is used in older children and adolescents with type 2 diabetes under specialist supervision, but the fixed-dose combination is not recommended for this age group. For pediatric type 2 diabetes, treatment should follow current pediatric guidelines (for example ISPAD and ADA), typically with metformin and/or insulin.
Elderly Patients
Elderly patients (aged 65 years and over) can use Ristfor, but additional caution is needed because kidney function tends to decline with age. Dose and ongoing suitability depend on eGFR rather than chronological age. Kidney function should be assessed before starting treatment and at least annually thereafter, and more frequently in the very elderly or when another medicine that affects kidney function is started. Older patients are also more vulnerable to dehydration (for example during heat waves, gastroenteritis, or diuretic therapy), which can increase lactic acidosis risk.
Driving and Operating Machinery
Ristfor itself has no or negligible direct influence on the ability to drive or use machines. However, hypoglycemia can impair concentration and reaction time, especially when Ristfor is combined with a sulfonylurea or insulin. Dizziness and drowsiness have also been reported with sitagliptin. Patients should be informed about the symptoms of hypoglycemia and take precautions when driving or operating machinery, particularly at the start of treatment or after a dose change.
How Does Ristfor Interact with Other Drugs?
The most important drug interactions with Ristfor involve medicines that affect kidney function or increase lactic acidosis risk (iodinated contrast media, alcohol, NSAIDs, diuretics, ACE inhibitors), drugs that can raise blood sugar (glucocorticoids, beta-2 agonists), drugs that can cause hypoglycemia when combined with Ristfor (sulfonylureas, insulin), and digoxin, whose levels may rise slightly with sitagliptin.
Ristfor combines two active substances with different pharmacokinetic profiles. Sitagliptin is primarily eliminated unchanged by the kidneys via active tubular secretion and is not extensively metabolized by cytochrome P450 enzymes, so cytochrome-mediated interactions are limited. Metformin is also eliminated by the kidneys (via tubular secretion through the organic cation transporter OCT2). As a result, most of the clinically important interactions relate to drugs that compete for renal elimination, reduce renal function, or have overlapping pharmacodynamic effects on glucose metabolism.
Always tell your doctor or pharmacist about every medicine you are taking, including over-the-counter medicines, herbal products, and nutritional supplements. This is particularly important before any imaging with contrast media, before surgery, or when starting another new medicine.
| Interacting Drug / Class | Effect | Clinical Significance | Recommendation |
|---|---|---|---|
| Iodinated contrast media | Potential acute decline in renal function; increased risk of lactic acidosis | Major | Stop Ristfor before or at the time of the procedure; resume only after kidney function is reassessed and stable (typically ≥ 48 hours) |
| Alcohol (acute intoxication, chronic abuse) | Increases lactic acidosis risk; may mask or worsen hypoglycemia | Major | Avoid excessive alcohol intake; binge drinking is particularly dangerous |
| Sulfonylureas (glimepiride, glipizide, etc.) | Increased risk of hypoglycemia | Major | Consider reducing sulfonylurea dose when initiating Ristfor |
| Insulin | Increased risk of hypoglycemia | Major | Reduce insulin dose to minimize hypoglycemia |
| ACE inhibitors, ARBs, diuretics, NSAIDs | May reduce renal function, increasing metformin accumulation and lactic acidosis risk | Moderate | Monitor renal function; consider temporary interruption in acute illness or dehydration |
| Cationic drugs (cimetidine, dolutegravir, ranolazine) | Competition for renal tubular transport; may increase metformin levels | Moderate | Monitor glycemic control closely; dose adjustment may be needed |
| Glucocorticoids (prednisolone, dexamethasone) | Raise blood glucose and may reduce glucose tolerance | Moderate | Monitor blood glucose; dose adjustment of Ristfor or additional therapy may be required |
| Beta-2 agonists (salbutamol, terbutaline) | Transient hyperglycemia via beta-2 receptor stimulation | Moderate | Monitor blood glucose, particularly in hospitalized or acutely ill patients |
| Digoxin | Slight increase in digoxin plasma concentration (approximately 11% AUC increase) | Minor | Consider monitoring digoxin levels, especially in patients with narrow therapeutic margins |
| Organic cation transporter (OCT) inhibitors | Altered renal clearance of metformin | Moderate | Monitor glycemic control and renal function |
Major Interactions
The most clinically critical interaction relates to iodinated contrast agents used in CT scans, coronary angiography, and similar imaging studies. These agents can cause transient or permanent reductions in kidney function, which in turn causes metformin to accumulate. Ristfor should be discontinued before or at the time of the procedure and withheld for at least 48 hours; treatment should only resume when renal function has been reassessed and confirmed to be stable. Similarly, Ristfor should be paused in the peri-operative period for major surgery requiring general, spinal, or epidural anaesthesia.
When Ristfor is combined with a sulfonylurea or insulin, the risk of hypoglycemia increases substantially, because these medicines directly stimulate insulin secretion. Clinical trials have shown that reducing the sulfonylurea or insulin dose when Ristfor is added can maintain glycemic benefits while minimizing hypoglycemia. Signs of hypoglycemia include sweating, shakiness, rapid heartbeat, hunger, confusion, and dizziness.
Minor and Pharmacodynamic Interactions
Several commonly used medicines tend to raise blood glucose and can therefore counteract the effect of Ristfor, potentially requiring dose adjustment. These include glucocorticoids (oral or inhaled at high doses), beta-2 adrenergic agonists used for asthma, thiazide diuretics, and some atypical antipsychotic drugs. In the opposite direction, ACE inhibitors can enhance the glucose-lowering effect, and at the same time they can reduce kidney function in vulnerable patients, which is why monitoring is important.
Co-administration of sitagliptin with digoxin was associated with a small increase in digoxin plasma concentration. This effect is usually not clinically relevant, but digoxin has a narrow therapeutic window, so periodic monitoring is reasonable in patients with cardiac disease or reduced renal function.
What Is the Correct Dosage of Ristfor?
The usual adult dose of Ristfor 50 mg/850 mg is one tablet twice daily with meals, giving a total of 100 mg sitagliptin and 1,700 mg metformin per day. The dose should be individualized based on the patient's existing therapy, tolerability, and kidney function. Swallow tablets whole with water. Do not crush or chew.
Always take Ristfor exactly as your doctor has prescribed. The total daily dose of sitagliptin should not exceed 100 mg, and the metformin component should be titrated according to tolerability and kidney function. Ristfor is taken with meals because food reduces the gastrointestinal side effects caused by metformin, particularly at treatment initiation.
| Patient Group | Kidney Function (eGFR) | Recommended Regimen | Total Daily Dose |
|---|---|---|---|
| Adults on metformin alone, needing add-on | eGFR ≥ 60 mL/min | 50 mg/850 mg twice daily with meals | 100 mg sitagliptin + 1,700 mg metformin |
| Adults switching from separate tablets | eGFR ≥ 60 mL/min | Match the existing doses of each component, usually 50 mg/850 mg twice daily | Equivalent to previous therapy |
| Adults with mild renal impairment | eGFR 60–89 mL/min | 50 mg/850 mg twice daily with meals | No dose adjustment required |
| Adults with moderate renal impairment (CKD 3a) | eGFR 45–59 mL/min | Use with caution; maximum metformin 2,000 mg/day; consider lower strengths or alternative regimens | Monitor eGFR every 3–6 months |
| Adults with moderate renal impairment (CKD 3b) | eGFR 30–44 mL/min | Ristfor not recommended; consider separate reduced-dose components or alternative therapy | Switch to sitagliptin 50 mg once daily ± reduced metformin |
| Adults with severe renal impairment | eGFR < 30 mL/min | Contraindicated | Do not use Ristfor |
| Elderly (≥ 65 years) | Based on eGFR | Doses as per eGFR above; monitor kidney function more frequently | Individualized |
| Children (< 18 years) | N/A | Not recommended | N/A |
Adults
Standard adult dose of Ristfor 50 mg/850 mg
For most adults with type 2 diabetes and normal or mildly impaired kidney function, the usual dose is one 50 mg/850 mg tablet twice daily, taken with meals (typically breakfast and the evening meal). This delivers 100 mg of sitagliptin and 1,700 mg of metformin per day. Taking the tablet with food reduces gastrointestinal side effects such as nausea, abdominal discomfort, and diarrhea.
If you are new to metformin, your doctor may choose to start with metformin alone at a low dose, titrate it up over several weeks, and then switch to Ristfor once you tolerate the target metformin dose. This gradual titration reduces stomach-related side effects. If you are switching from separate sitagliptin and metformin tablets, your doctor will usually prescribe the Ristfor strength that matches the total doses of your current therapy.
When Ristfor is added to a sulfonylurea or insulin, the dose of the sulfonylurea or insulin may need to be reduced to reduce the risk of hypoglycemia. Your doctor may advise home blood glucose monitoring during the first few weeks to guide dose adjustments.
Children
Ristfor is not recommended in children and adolescents under 18 years of age because the safety and efficacy of the fixed-dose combination have not been established in this population. For paediatric type 2 diabetes, current international guidelines recommend lifestyle intervention plus metformin, and in some cases insulin or GLP-1 receptor agonists approved for pediatric use.
Elderly
There is no fixed dose adjustment based on age. However, elderly patients commonly have reduced kidney function and are more vulnerable to dehydration and acute illness – all of which can precipitate lactic acidosis with metformin-containing medicines. Your doctor will assess your eGFR before starting Ristfor, then check it at least annually (and more frequently if it is borderline or if you start another drug that affects kidney function). In clinical practice, elderly patients benefit particularly from the low hypoglycemia risk of the sitagliptin component.
Missed Dose
If you forget to take a dose, take it as soon as you remember – ideally with food. However, if it is almost time for your next scheduled dose, skip the missed one and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one; this can increase the risk of gastrointestinal side effects and does not give better blood sugar control. If you are unsure, contact your pharmacist or doctor.
Overdose
If you accidentally take more Ristfor than prescribed, contact your doctor, a hospital emergency department, or a poison control center immediately. Very high doses of metformin can cause lactic acidosis, which is a medical emergency and requires rapid assessment, correction of metabolic disturbances, and sometimes haemodialysis to remove metformin. Overdose of sitagliptin is usually better tolerated – single doses up to 800 mg have been administered in clinical studies without major adverse events – but any overdose should be evaluated by a healthcare professional. Treatment is supportive; sitagliptin is only modestly removed by haemodialysis.
Suddenly stopping Ristfor can lead to a rapid rise in blood sugar, especially if you have been taking it for a long time. If you experience side effects, are preparing for surgery, or are starting another medication, talk to your healthcare provider first. Together you can plan a safe dose adjustment, a temporary pause, or a switch to an alternative treatment.
What Are the Side Effects of Ristfor?
The most common side effects of Ristfor are gastrointestinal (nausea, diarrhea, abdominal pain, loss of appetite) from the metformin component, plus occasional headache and upper respiratory tract infection from the sitagliptin component. Hypoglycemia is common when Ristfor is combined with a sulfonylurea or insulin. Rare but serious adverse events include lactic acidosis, pancreatitis, severe allergic reactions, and bullous pemphigoid.
Like all medicines, Ristfor can cause side effects, although not everyone experiences them. Most side effects are mild to moderate, appear early in treatment, and improve with time or by taking the tablet with meals. Serious adverse events are uncommon but require prompt recognition and action.
- Signs of lactic acidosis: unusual tiredness, muscle cramps, difficulty breathing, severe abdominal pain, feeling very cold, or a slow or irregular heartbeat
- Severe and persistent abdominal pain that may radiate to the back, with or without nausea or vomiting – possible pancreatitis
- Severe allergic reaction: rash, hives, blisters, peeling skin, or swelling of the face, lips, tongue, or throat causing difficulty breathing or swallowing
- Blisters or erosions on the skin or mucous membranes – possible bullous pemphigoid
- Yellowing of the skin or eyes (jaundice) – possible liver injury
Very Common Side Effects
May affect more than 1 in 10 people
- Hypoglycemia (low blood sugar) – particularly when Ristfor is combined with a sulfonylurea or insulin
- Nausea, usually early in treatment and transient
- Diarrhea, often dose-related and improved by taking the tablet with food
Common Side Effects
May affect up to 1 in 10 people
- Abdominal pain, dyspepsia (indigestion), or stomach discomfort
- Vomiting
- Flatulence (gas) or bloating
- Loss of appetite
- Metallic taste in the mouth
- Headache
- Upper respiratory tract infection
- Stuffy or runny nose and sore throat (nasopharyngitis)
- Dizziness, drowsiness
- Mild rash
Uncommon Side Effects
May affect up to 1 in 100 people
- Osteoarthritis or joint pain
- Pain in arms or legs
- Itching (pruritus)
- Constipation
- Peripheral edema (swelling of hands or feet), especially when combined with pioglitazone
- Dry mouth (particularly when combined with insulin)
- Reduced appetite
Rare Side Effects
May affect up to 1 in 1,000 people
- Decreased platelet count (thrombocytopenia)
- Skin disorders (for example eczema)
Very Rare or Post-marketing Reports
Frequency cannot be estimated from available data
- Lactic acidosis (very rare but potentially fatal)
- Vitamin B12 deficiency, sometimes associated with megaloblastic anaemia (usually with long-term use)
- Acute pancreatitis, including haemorrhagic or necrotizing pancreatitis
- Severe hypersensitivity reactions: anaphylaxis, angioedema, Stevens-Johnson syndrome
- Bullous pemphigoid (blistering skin condition)
- Acute kidney injury (sometimes requiring dialysis)
- Interstitial lung disease
- Liver function abnormalities and hepatitis (reversible with discontinuation)
- Severe, sometimes disabling joint pain (arthralgia)
Gastrointestinal Tolerability
Stomach-related symptoms are by far the most frequent reason patients stop metformin-containing medicines. Taking Ristfor with meals, starting at a lower metformin dose when possible, and allowing a few weeks for the body to adjust can substantially reduce nausea and diarrhea. If symptoms persist or are severe, your doctor may consider switching to an alternative strength, a modified-release metformin formulation, or another treatment class.
Hypoglycemia in Combination Therapy
On its own, Ristfor rarely causes hypoglycemia because neither sitagliptin nor metformin increases insulin release when glucose is normal. However, when Ristfor is combined with a sulfonylurea or insulin, hypoglycemia becomes common. Classic symptoms include sweating, trembling, pounding heart, hunger, blurred vision, dizziness, confusion, and, in severe cases, loss of consciousness or seizures. Carry a quick source of sugar (glucose tablets, juice, or sweets) and inform family members about how to recognize and treat low blood sugar.
Reporting Side Effects
Reporting suspected adverse reactions after a medicine has been authorized is an essential part of ongoing safety monitoring. Patients and healthcare professionals can report side effects to their national drug regulatory authority – for example the FDA MedWatch program in the United States, the Yellow Card Scheme via the MHRA in the United Kingdom, or the national competent authority in any other country. These reports help identify rare risks and inform prescribing guidance for the whole community.
How Should You Store Ristfor?
Store Ristfor tablets below 30°C (86°F) in the original blister pack to protect against moisture. Keep out of sight and reach of children. Do not use after the expiry date printed on the blister or carton. Dispose of unused tablets through a pharmacy take-back scheme rather than in household waste or down the toilet.
Proper storage of Ristfor helps ensure that the tablets remain effective and safe throughout their shelf life. Follow these storage guidelines:
- Temperature: Store below 30°C (86°F). Protect from excessive heat such as in a hot car or near a radiator.
- Moisture: Keep tablets in the original blister pack until you are ready to take them. Both sitagliptin and metformin can be sensitive to humidity.
- Light: Avoid direct sunlight; store the carton in a cool, dry place such as a cupboard.
- Children: Keep all medicines out of the sight and reach of children. Accidental ingestion of metformin-containing products can be serious.
- Expiry date: Do not use Ristfor after the expiry date ("EXP") printed on the blister foil or outer carton. The expiry refers to the last day of the indicated month.
- Damaged or discolored tablets: Do not use tablets that appear damaged, chipped, or discolored.
Do not dispose of medicines via wastewater or household waste. Return unused or expired medicines to a pharmacy or approved medical waste collection service. These measures help protect the environment and prevent accidental exposure.
What Does Ristfor 50 mg/850 mg Contain?
Each Ristfor 50 mg/850 mg film-coated tablet contains sitagliptin (as sitagliptin phosphate monohydrate) equivalent to 50 mg sitagliptin and 850 mg metformin hydrochloride. Inactive ingredients include microcrystalline cellulose, povidone, sodium lauryl sulfate, sodium stearyl fumarate, and a film coating containing polyvinyl alcohol, macrogol, talc, titanium dioxide, and iron oxides.
Active Ingredients
The active substances in each Ristfor 50 mg/850 mg tablet are:
- Sitagliptin 50 mg (present as sitagliptin phosphate monohydrate). Sitagliptin is the selective DPP-4 inhibitor responsible for enhancing incretin hormone activity and boosting post-meal insulin secretion.
- Metformin hydrochloride 850 mg. Metformin is the biguanide responsible for reducing hepatic glucose production and improving insulin sensitivity.
Inactive Ingredients (Excipients)
The excipients ensure that the active ingredients are stable, properly absorbed, and compressed into a consistent tablet. Typical excipients in Ristfor film-coated tablets include:
- Tablet core: microcrystalline cellulose (E460), povidone (E1201), sodium lauryl sulfate, and sodium stearyl fumarate
- Film coating: poly(vinyl alcohol), macrogol 3350, talc (E553b), titanium dioxide (E171), and red and black iron oxides (E172) to give the tablet its characteristic color and provide moisture protection
Ristfor tablets contain less than 1 mmol of sodium (less than 23 mg) per tablet, meaning they are essentially "sodium-free". This is relevant for patients on a controlled-sodium diet.
Tablet Appearance and Packaging
Ristfor 50 mg/850 mg film-coated tablets are typically capsule-shaped (oval), pink, with an identifying imprint. Tablets are supplied in opaque PVC/PE/PVDC-aluminum blister packs. Common pack sizes include 14, 28, 56, 98, and 196 (multipacks) film-coated tablets, although not all pack sizes may be marketed in every country.
Check the patient information leaflet supplied in the package and the blister itself to confirm that you have the correct strength and expiry date. If anything looks unusual, contact your pharmacist before taking the tablet.
Frequently Asked Questions About Ristfor
Ristfor is a fixed-dose combination tablet containing sitagliptin (a DPP-4 inhibitor) and metformin (a biguanide). It is used to treat type 2 diabetes mellitus in adults whose blood sugar is not adequately controlled by metformin alone, in combination with a sulfonylurea or insulin when these regimens are not enough, or as a simpler single-tablet replacement for patients already taking both drugs separately. It is not used for type 1 diabetes or diabetic ketoacidosis.
The usual dose is one 50 mg/850 mg tablet twice daily, taken with meals (typically breakfast and the evening meal). This provides 100 mg sitagliptin and 1,700 mg metformin per day. If you are switching from separate sitagliptin and metformin tablets, your doctor will usually prescribe the Ristfor strength that matches your previous total daily doses. Dose adjustments are based on kidney function, tolerability, and any concurrent diabetes medicines.
Most common side effects are gastrointestinal, reflecting the metformin component: nausea, diarrhea, abdominal pain, loss of appetite, and a metallic taste in the mouth. These usually appear early in treatment and often improve with time or by taking the tablet with food. Other common effects include headache, dizziness, upper respiratory infections, and hypoglycemia when Ristfor is combined with a sulfonylurea or insulin. Long-term use can reduce vitamin B12 absorption, so periodic monitoring is recommended.
Lactic acidosis is a very rare but serious side effect of metformin-containing medicines, including Ristfor. Risk increases with kidney impairment, dehydration, severe infection, heart failure, liver disease, excessive alcohol intake, or the use of iodinated contrast agents. Seek emergency medical care immediately if you develop muscle cramps, unusual tiredness, difficulty breathing, severe abdominal pain, feeling very cold, or an irregular heartbeat. To reduce risk, stay well hydrated, limit alcohol, and tell healthcare professionals you are taking Ristfor before any imaging with contrast or major surgery.
Yes. Ristfor should be temporarily stopped before or at the time of imaging procedures using iodinated contrast media (such as CT with contrast or angiography) and resumed only after kidney function has been reassessed and is stable, typically after at least 48 hours. Similarly, Ristfor should be discontinued at the time of or shortly before major surgery requiring general, spinal, or epidural anaesthesia. Your doctor or anaesthesiologist will tell you when it is safe to restart.
Ristfor is generally weight-neutral or modestly weight-favorable. Sitagliptin is weight-neutral, while metformin is associated with small weight loss or weight stability in many patients. This profile contrasts with sulfonylureas, insulin, and thiazolidinediones, which tend to cause weight gain. For patients in whom weight management is a priority, Ristfor can be an attractive option, but a GLP-1 receptor agonist or SGLT2 inhibitor may offer greater weight reduction.
Ristfor is not recommended during pregnancy or breastfeeding. Safety data in pregnant women are insufficient for the sitagliptin component, and while metformin is sometimes used during pregnancy under specialist care (for example in polycystic ovary syndrome or gestational diabetes), the fixed-dose combination Ristfor is not approved for this use. Insulin is generally the preferred treatment for diabetes during pregnancy because it allows precise adjustment. If you are pregnant or planning a pregnancy, contact your doctor to discuss safe alternatives.
The information on this page is based on international clinical guidelines and peer-reviewed evidence, including the EMA Summary of Product Characteristics for Ristfor (sitagliptin/metformin), the ADA Standards of Care in Diabetes 2025, NICE Guidelines for Type 2 Diabetes Management (NG28), the TECOS cardiovascular outcomes trial for sitagliptin published in the New England Journal of Medicine, and the WHO Model List of Essential Medicines. All medical claims follow evidence level 1A, the highest quality of evidence based on systematic reviews and randomized controlled trials.
References
- European Medicines Agency (EMA). Ristfor (sitagliptin/metformin hydrochloride) – Summary of Product Characteristics and EPAR. Last updated 2024. EMA – Ristfor EPAR
- European Medicines Agency (EMA). Janumet (sitagliptin/metformin) – Summary of Product Characteristics. EMA – Janumet EPAR
- American Diabetes Association (ADA). Standards of Care in Diabetes – 2025. Diabetes Care. 2025;48(Supplement 1). ADA Standards of Care 2025
- Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes (TECOS). N Engl J Med. 2015;373(3):232-242. doi:10.1056/NEJMoa1501352
- National Institute for Health and Care Excellence (NICE). Type 2 Diabetes in Adults: Management (NG28). Last updated 2024. NICE NG28
- World Health Organization (WHO). Model List of Essential Medicines – 23rd List. 2023. WHO Essential Medicines List
- U.S. Food and Drug Administration (FDA). Janumet (sitagliptin/metformin) Prescribing Information. FDA Prescribing Information
- Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. 2020;16(11):642-653. doi:10.1038/s41574-020-0399-8
- Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. 2019;15(10):569-589. doi:10.1038/s41574-019-0242-2
- Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668-2675. doi:10.1001/jama.2014.15298
About Our Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, which includes board-certified physicians specializing in endocrinology, diabetology, and clinical pharmacology. Our editorial process ensures that all content meets the highest standards of medical accuracy, following the GRADE evidence framework and international clinical guidelines.
All drug information is verified against the European Medicines Agency (EMA) Summary of Product Characteristics, FDA prescribing information, and current clinical guidelines (ADA, NICE, WHO).
Evidence Level 1A – based on systematic reviews, meta-analyses of randomized controlled trials, and landmark cardiovascular outcomes trials (TECOS).
No pharmaceutical company sponsorship or advertising. All content is editorially independent with no commercial funding or conflicts of interest.
This article is reviewed and updated regularly to reflect the latest clinical evidence, regulatory changes, and guideline updates.